{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:00:35Z","timestamp":1792047635117,"version":"4.4.0"},"reference-count":50,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2019,8,12]]},"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:p>SF3B1 is the largest subunit of the Spliceosome Factor 3b (SF3B) complex and part of the U2 small nuclear ribosomal protein. It functions as an important part of spliceosomal assembly, converting precursor messenger RNA (mRNA) to mRNA ready for ribosomal translation. Mutations of <jats:italic>SF3B1<\/jats:italic> are commonly seen in myelodysplastic syndromes with ring sideroblasts (MDS-RS)and MDS\/myeloproliferative neoplasm (MPN-RS-T). These mutations are typically heterozygous missense substitutions, of which, 55% involve K700E. MDS-RS and MDS\/MPN-RS-T usually carry a more favourable prognosis than other subtypes of MDS. <jats:italic>SF3B1<\/jats:italic> itself does not influence survival in these conditions, but does correlate with increased thrombotic risk. Mutated <jats:italic>SF3B1<\/jats:italic> is present in 9%\u201315% of chronic lymphocytic leukaemia cases and on its own correlates with improved responsiveness to ibrutinib, but is associated with additional adverse genetic abnormalities including <jats:italic>TP53<\/jats:italic> and <jats:italic>ATM<\/jats:italic> mutations, which traditionally confer adverse outcomes.<\/jats:p>","DOI":"10.1136\/jclinpath-2019-205895","type":"journal-article","created":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T17:19:14Z","timestamp":1567271954000},"page":"778-782","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Somatic <i>SF3B1<\/i> mutations in myelodysplastic syndrome with ring sideroblasts and chronic lymphocytic leukaemia"],"prefix":"10.1136","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3248-9894","authenticated-orcid":false,"given":"Allister","family":"Foy","sequence":"first","affiliation":[{"name":"Haematology, Belfast Health and Social Care Trust, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0773-0204","authenticated-orcid":false,"given":"Mary Frances","family":"McMullin","sequence":"additional","affiliation":[{"name":"Haematology, Belfast Health and Social Care Trust, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,8,31]]},"reference":[{"key":"2025092504100228000_72.11.778.1","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a003707","article-title":"Spliceosome structure and function","volume":"3","author":"Will","year":"2011","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2025092504100228000_72.11.778.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2124"},{"key":"2025092504100228000_72.11.778.3","doi-asserted-by":"publisher","DOI":"10.1126\/science.1084155"},{"key":"2025092504100228000_72.11.778.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3742"},{"key":"2025092504100228000_72.11.778.5","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2242-0"},{"key":"2025092504100228000_72.11.778.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2016.08.036"},{"key":"2025092504100228000_72.11.778.7","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdf480"},{"key":"2025092504100228000_72.11.778.8","doi-asserted-by":"publisher","DOI":"10.1101\/gad.12.10.1409"},{"key":"2025092504100228000_72.11.778.9","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.16.4536"},{"key":"2025092504100228000_72.11.778.10","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.18.8.4752"},{"key":"2025092504100228000_72.11.778.11","doi-asserted-by":"publisher","DOI":"10.1021\/bi060429o"},{"key":"2025092504100228000_72.11.778.12","unstructured":"NCBI gene resource . SF3B1 splicing factor 3 subunit 1 [Homo sapiens (Human)], 2019. Available: https:\/\/www.ncbi.nlm.nih.gov\/gene [Accessed 17 Mar 2019]."},{"key":"2025092504100228000_72.11.778.13","unstructured":"Gene Cards Human Gene Database . Sf3B1 gene (protein coding). Available: https:\/\/www.genecards.org [Accessed 17 Mar 2019]."},{"key":"2025092504100228000_72.11.778.14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13405"},{"key":"2025092504100228000_72.11.778.15","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.331"},{"key":"2025092504100228000_72.11.778.16","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06063-x","article-title":"Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia","volume":"9","author":"Shiozawa","year":"2018","journal-title":"Nat Commun"},{"key":"2025092504100228000_72.11.778.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-776070"},{"key":"2025092504100228000_72.11.778.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-39591-7","article-title":"Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability","volume":"9","author":"Liberante","year":"2019","journal-title":"Sci Rep"},{"key":"2025092504100228000_72.11.778.19","doi-asserted-by":"publisher","DOI":"10.1038\/nature10496"},{"key":"2025092504100228000_72.11.778.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103283"},{"key":"2025092504100228000_72.11.778.21","unstructured":"Swerdlow SH , Campo E , Harris NL , et al . WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Edition. Lyon: International Agency for Research on Cancer, 2017."},{"key":"2025092504100228000_72.11.778.22","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10615","article-title":"Cancer-Associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage","volume":"7","author":"Alsafadi","year":"2016","journal-title":"Nat Commun"},{"key":"2025092504100228000_72.11.778.23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"2025092504100228000_72.11.778.24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377275"},{"key":"2025092504100228000_72.11.778.25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377994"},{"key":"2025092504100228000_72.11.778.26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-427641"},{"key":"2025092504100228000_72.11.778.27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-415356"},{"key":"2025092504100228000_72.11.778.28","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.232"},{"key":"2025092504100228000_72.11.778.29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-633537"},{"key":"2025092504100228000_72.11.778.30","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2551-y"},{"key":"2025092504100228000_72.11.778.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.07.013"},{"key":"2025092504100228000_72.11.778.32","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.119032"},{"key":"2025092504100228000_72.11.778.33","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.216"},{"key":"2025092504100228000_72.11.778.34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-736421"},{"key":"2025092504100228000_72.11.778.35","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23373"},{"key":"2025092504100228000_72.11.778.36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.3314"},{"key":"2025092504100228000_72.11.778.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2018.11.022"},{"key":"2025092504100228000_72.11.778.38","doi-asserted-by":"crossref","unstructured":"Hou H-A , Liu C-Y , Kuo Y-Y , et al . Splicing factor mutations predict poor prognosis in patients with <i>de novo<\/i> acute myeloid leukemia. Oncotarget 2016;7.doi:10.18632\/oncotarget.7000","DOI":"10.18632\/oncotarget.7000"},{"key":"2025092504100228000_72.11.778.39","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28011"},{"key":"2025092504100228000_72.11.778.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109016"},{"key":"2025092504100228000_72.11.778.41","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.263"},{"key":"2025092504100228000_72.11.778.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.12.013"},{"key":"2025092504100228000_72.11.778.43","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv303"},{"key":"2025092504100228000_72.11.778.44","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.196"},{"key":"2025092504100228000_72.11.778.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.04.001"},{"key":"2025092504100228000_72.11.778.46","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2042.2042","article-title":"11Q deletion (del11q) is not a prognostic factor for adverse outcomes for patients with chronic lymphocytic Leukemia\/Small lymphocytic lymphoma (CLL\/SLL) treated with ibrutinib: pooled data from 3 randomized phase 3 studies","volume":"128","author":"Kipps","year":"2016","journal-title":"Blood"},{"key":"2025092504100228000_72.11.778.47","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2523"},{"key":"2025092504100228000_72.11.778.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.01.023"},{"key":"2025092504100228000_72.11.778.49","doi-asserted-by":"publisher","DOI":"10.1038\/nature11017"},{"key":"2025092504100228000_72.11.778.50","doi-asserted-by":"crossref","unstructured":"Fu X , Tian M , Gu J , et al . SF3B1 mutation is a poor prognostic indicator in luminal B and progesterone receptor-negative breast cancer patients. Oncotarget 2017;8.doi:10.18632\/oncotarget.22983","DOI":"10.18632\/oncotarget.22983"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2019-205895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T11:10:11Z","timestamp":1758798611000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2019-205895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,31]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,10,17]]},"published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1136\/jclinpath-2019-205895"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2019-205895","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,31]]}}}